Ligands organométalliques

<p>Osmanthuside H is a natural compound, specifically a phenylethanoid glycoside, which is predominantly sourced from the plant Osmanthus fragrans, as well as other related species. This compound is characterized by a specific glycosidic linkage that contributes to its stability and bioactivity. The mode of action of Osmanthuside H primarily involves its significant antioxidant properties, attributed to the presence of its phenolic structure and glycosidic moiety. This facilitates its role in scavenging free radicals and reducing oxidative stress within biological systems.</p>

<p>L-MobileTrex is an advanced analytical technology platform, which is a product of cutting-edge research in data science and computational modeling. This platform operates by integrating multi-dimensional datasets through sophisticated algorithms, providing enhanced data visualization and interpretability.</p>

<p>VS1 is a novel synthetic peptide, which is engineered to function as an antimicrobial agent. This peptide originates from recombinant DNA technology, providing a customizable approach to target specific microbial strains. Its mode of action involves the selective disruption of microbial cell membranes, leading to the lysis and consequent death of the target cell. The specificity of VS1 for microbial cells over mammalian cells minimizes off-target effects, making it a highly effective agent for infection control.</p>

<p>A novel muscarinic M3 receptor antagonist with high selectivity for M3 over M2 receptors</p>

<p>Alvameline is a muscarinic receptor agonist, which is a small molecule drug derived from synthetic chemistry processes. Its primary source is the intricate design of pharmacologically active compounds targeting the central nervous system. Alvameline exerts its effects through selective agonism of muscarinic acetylcholine receptors, playing a pivotal role in modulating neurotransmission. Specifically, by activating these receptors, it enhances cholinergic signaling, which is crucial for cognitive functions such as memory and attention.</p>

<p>CAY10727 is a potent biochemical inhibitor, which is derived from synthetic sources with specific action targeting cyclooxygenase-2 (COX-2) enzymes. It functions by selectively blocking the enzymatic activity of COX-2, which plays a critical role in the biosynthesis of prostaglandins involved in inflammatory responses. This targeted inhibition allows the study of COX-2-related pathways without interference from COX-1, which is significant for maintaining gastrointestinal integrity.The use and applications of CAY10727 are primarily in research settings where understanding the pathways involved in inflammation, pain, and cancer progression are critical. This compound is utilized in various in vitro experiments to delineate the role of COX-2 in cellular and molecular contexts, enabling scientists to dissect complex signaling networks. Given its specificity, CAY10727 is instrumental in the development of new therapeutic approaches where selective COX-2 inhibition might offer benefits over non-selective inhibitors.</p>

<p>FR-190809 is a peptide that acts as an inhibitor of protein interactions. It binds to the receptor and blocks the activation of phospholipase C. FR-190809 also stimulates the production of cyclic AMP, which in turn activates protein kinase A, thereby inhibiting the production of cAMP. FR-190809 has been shown to have a high purity and is used as a research tool for studying protein interactions.</p>

<p>PF-06658607 is an investigational drug that is classified as a small molecule inhibitor. It is developed from synthetic chemical sources with a specific mode of action targeting aggrecanases, enzymes that degrade aggrecan, a critical component of cartilage. By inhibiting these enzymes, PF-06658607 aims to prevent the breakdown of cartilage in joints.</p>

<p>CB-1158 is an arginase inhibitor, which is a small molecule derived from a synthetic source designed to modulate immune functions. Its mode of action involves the inhibition of the arginase enzyme, a key player in the urea cycle responsible for the hydrolysis of arginine into ornithine and urea. By blocking arginase, CB-1158 effectively prevents the depletion of extracellular arginine, a vital amino acid required for the activation and proliferation of T cells within the immune system. This inhibition leads to enhanced immune responses against tumors.</p>

<p>BCR-ABL-IN-2 is a small molecule inhibitor, which is synthetically derived for precision-targeted therapeutic applications. It functions as a selective inhibitor of the BCR-ABL fusion protein, a tyrosine kinase that is constitutively active in certain leukemias, particularly chronic myeloid leukemia (CML). The product is engineered via chemical synthesis to ensure high specificity and selectivity in binding to the ATP-binding site of the BCR-ABL protein, effectively inhibiting its kinase activity.</p>

<p>AR-R 17779 is a selective agonist for α7 nicotinic acetylcholine receptors or nAChRs. It is suggested that AR-R 17779 reduces formation of atherosclerotic plaques and abdominal aortic aneurysms in apolipoprotein E-deficient mice.</p>

<p>Microtubule-stabilizing agent; antineoplastic;</p>

<p>Prodrug of dihydroartemisin (DHA); antimalarial</p>

<p>Trypsin (EC 3.4.21.4) is a protease that hydrolyses proteins by cleaving the peptide bond at the carboxyl side of the positively charged amino acid (Lysine or Arginine). Trypsin belongs to a family of serine proteases, as it has a serine in its active site. Trypsin can be inhibited by using trypsin inhibitor Alpha 1 Antitrypsin.</p>

<p>Inhibitor of PARP1 and PARP2 enzymes</p>

<p>UM171 is a small-molecule compound, which is derived from synthetic chemical processes with properties that enable the expansion of human hematopoietic stem cells (HSCs) in vitro. It acts by targeting and modulating specific cellular pathways to enhance the self-renewal and proliferation of HSCs without inducing differentiation.<br><br>The primary application of UM171 lies in the field of regenerative medicine and transplantation. By facilitating the expansion of HSCs, UM171 holds significant potential in improving the outcomes of bone marrow and cord blood transplants. This is particularly relevant in contexts where donor cell availability is limited or where augmenting the engraftment potential of HSCs is critical. The ability to expand HSCs ex vivo opens avenues for improved treatment of hematological disorders, potentially allowing for more effective and accessible transplant therapies. Researchers are exploring its utility in diverse experimental setups, aiming to translate this compound's capabilities into clinical settings to enhance patient outcomes in hematopoietic recovery and therapy.</p>

<p>TAPI-1 is an inhibitor of TACE (TNF-α converting enzyme, also known as ADAM17) and matrix metalloproteinases (MMPs). It blocks the shedding of several cell surface proteins, including tumor necrosis factor-alpha (TNF-α), IL-6 receptor, and TNF receptors p60 (TNFRI) and p80 (TNFRII).</p>

<p>Please enquire for more information about Elafibranor including the price, delivery time and more detailed product information at the technical inquiry form on this page</p>

<p>Amelubant is a synthetic compound designed for use in detailed biochemical research and therapeutic investigations. As a product derived from innovative chemical synthesis techniques, Amelubant is engineered to interact with particular biological pathways, predominantly in the field of inflammatory response modulation. Its mode of action involves specific binding to target receptors, influencing downstream signaling cascades.</p>

<p>SNIPER(ABL)-058 is a cutting-edge selective protein degrader, developed from the field of chemical biology. It is based on a bifunctional small molecule that acts as a degrader by recruiting the ubiquitin-proteasome system to specifically tag the target protein for degradation. This compound is synthesized through precise chemical modifications designed to form specific interactions with its target, namely the BCR-ABL protein, a critical driver in certain cancer pathways.</p>